12/5
09:40 am
stok
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
Low
Report
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
12/5
09:00 am
stok
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Low
Report
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
12/4
05:12 pm
stok
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
Low
Report
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
12/1
07:30 am
stok
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Low
Report
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
11/28
10:18 am
stok
Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]
Low
Report
Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]
11/21
05:31 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/18
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
11/17
07:30 am
stok
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Low
Report
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
11/10
01:17 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
11/5
04:01 pm
stok
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
11/5
12:11 pm
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $28.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $28.00 price target on by analysts at Canaccord Genuity Group Inc..
11/5
09:37 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $22.00 to $32.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $22.00 to $32.00. They now have an "outperform" rating on the stock.
11/5
08:08 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $39.00 price target on the stock.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $39.00 price target on the stock.
11/4
04:01 pm
stok
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Medium
Report
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/3
11:03 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at JPMorgan Chase & Co. from $15.00 to $25.00. They now have a "neutral" rating on the stock.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at JPMorgan Chase & Co. from $15.00 to $25.00. They now have a "neutral" rating on the stock.
10/30
04:51 pm
stok
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates [Yahoo! Finance]
Medium
Report
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates [Yahoo! Finance]
10/30
04:30 pm
stok
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
Medium
Report
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
10/20
07:30 am
stok
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
Low
Report
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
10/19
03:31 am
stok
H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) [Yahoo! Finance]
Low
Report
H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) [Yahoo! Finance]
10/16
04:30 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10/14
08:08 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at BTIG Research from $28.00 to $39.00. They now have a "buy" rating on the stock.
High
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at BTIG Research from $28.00 to $39.00. They now have a "buy" rating on the stock.
10/10
08:06 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Needham & Company LLC from $22.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Needham & Company LLC from $22.00 to $35.00. They now have a "buy" rating on the stock.
10/9
11:25 pm
stok
Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome [Yahoo! Finance]
Low
Report
Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome [Yahoo! Finance]
10/9
04:30 pm
stok
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Low
Report
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
10/6
07:55 am
stok
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer [Yahoo! Finance]